In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia

Edwin Klumper*, Rob Pieters, Anjo J.P. Veerman, Dieuwke R. Huismans, Annemarie H. Loonen, Karel Hählen, Gertjan J.L. Kaspers, Elisabeth R. Van Wering, Reinhard Hartmann, Günter Henze

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Cellular drug resistance is thought to be an important cause of the poor prognosis for children with relapsed or refractory acute lymphoblastic leukemia (ALL), but it is unknown when, to which drugs, and to what extent resistance is present. We determined in vitro resistance to 13 drugs with the MTT assay. Compared with 141 children with initial ALL, cells from 137 children with relapsed ALL were significantly more resistant to glucocorticoids, L-asparaginase, anthracyclines, and thiopurines, but not to vinca-alkaloids, cytarabine, ifosfamide, and epipodophyllotoxins. Relapsed ALL cells expressed the highest level of resistance to glucocorticoids, with a median level 357- and >24-fold more resistant to prednisolone and dexamethasone, respectively, than initial ALL cells, whereas the resistance ratios for the other drugs differed from 0.8- to 1.9-fold. Intraindividual comparisons between initial and relapsed samples from 16 children with ALL showed that both de novo and acquired drug resistance were involved. Specific in vitro drug-resistance profiles were associated with high-risk relapsed ALL groups. In vitro drug resistance was also related to the clinical response to chemotherapy in relapsed/refractory childhood ALL. We conclude that drug resistance may explain the poor prognosis for children with relapsed/refractory ALL. These data may be helpful to design alternative treatment regimens for relapsed childhood ALL.

Original languageEnglish
Pages (from-to)3861-3868
Number of pages8
JournalBlood
Volume86
Issue number10
DOIs
Publication statusPublished - 15 Nov 1995

Cite this